What does FDA breakthrough status mean for a new spinal tumor drug? Learn about early results and treatment potential.

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, today announced the U.K.

A new analysis suggests having diabetes may significantly increase a person's risk of MS, though no evidence was found a ...

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a ...

Pediatric low-grade gliomas (pLGGs) exhibit distinct biological and clinical characteristics compared to adult gliomas, and their treatment strategies differ substantially from those used in adults.

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase ...

Discusses Unmet Needs and Advances in Dialysis Access with ATEV for Hemodialysis Patients April 28, 2026 8:00 AM ...

Pediatric low‑grade gliomas (pLGGs) have distinct biology and treatment strategies compared to adult gliomas. These Chinese consensus guidelines ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

Mild traumatic brain injury (mTBI) accounts for most head injury emergency department (ED) presentations, yet only a minority of patients have acute ...

Musculoskeletal care is facing a growing paradox: as demand rises and more procedures move into outpatient settings, it’s becoming harder, not easier, to get patients treated. A new wave of payer ...